Fresenius Medical Care Reports Strong 2025 Results, Issues Cautious 2026 Outlook Amid Headwinds

summarizeSummary

Fresenius Medical Care AG delivered robust financial performance in 2025, meeting or exceeding its financial outlook with significant growth in operating income and EPS, alongside margin expansion. However, the company's 2026 guidance signals a notable deceleration, with revenue expected to be broadly flat and operating income growth projected in the mid-single digits (positive or negative), citing significant additional headwinds. This cautious outlook for the near term is likely to be the primary market driver, overshadowing the strong past performance. Positively, the company continues to execute its FME25+ transformation program, exceeding savings targets, and is progressing with its EUR 1 billion share buyback program, which was previously announced on January 12, 2026, with the second tranche now underway. The reduction in net leverage also indicates improved financial health.

check_boxKey Events

• Strong Full-Year 2025 Performance

  The company reported full-year 2025 revenue of EUR 19,628 million (+5% at constant currency) and operating income (excluding special items) of EUR 2,212 million (+27% at constant currency), reaching the upper end of its financial outlook. EPS (excluding special items) grew by 44% to EUR 4.28.

• Significant Margin Expansion

  The operating income margin (excluding special items) improved to 11.3% for the full year 2025, up from 9.3% in 2024, placing it within the company's 2025 mid-term target band.

• Cautious 2026 Outlook

  For 2026, Fresenius Medical Care expects revenue growth to be broadly flat and operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate, citing significant additional headwinds.

• Accelerated Share Buyback Program

  The EUR 1.0 billion share buyback program is progressing ahead of schedule. The first tranche of EUR 600 million was completed on December 29, 2025, and the second tranche of EUR 414 million commenced on January 12, 2026, with an expected completion by May 8, 2026.

auto_awesomeAnalysis

Fresenius Medical Care AG delivered robust financial performance in 2025, meeting or exceeding its financial outlook with significant growth in operating income and EPS, alongside margin expansion. However, the company's 2026 guidance signals a notable deceleration, with revenue expected to be broadly flat and operating income growth projected in the mid-single digits (positive or negative), citing significant additional headwinds. This cautious outlook for the near term is likely to be the primary market driver, overshadowing the strong past performance. Positively, the company continues to execute its FME25+ transformation program, exceeding savings targets, and is progressing with its EUR 1 billion share buyback program, which was previously announced on January 12, 2026, with the second tranche now underway. The reduction in net leverage also indicates improved financial health.